scispace - formally typeset
C

Catharine I. Paules

Researcher at Penn State Milton S. Hershey Medical Center

Publications -  20
Citations -  3180

Catharine I. Paules is an academic researcher from Penn State Milton S. Hershey Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 10 publications receiving 1764 citations. Previous affiliations of Catharine I. Paules include Pennsylvania State University.

Papers
More filters
Journal ArticleDOI

Coronavirus Infections-More Than Just the Common Cold.

TL;DR: Yet another pathogenic HCoV, 2019 novel coronavirus (2019-nCoV), was recognized in Wuhan, China, and has caused serious illness and death, and the ultimate scope and effect of this outbreak is unclear at present.
Journal ArticleDOI

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.

Andre C. Kalil, +59 more
TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Journal ArticleDOI

SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis

TL;DR: A systematic review and meta-analysis of the duration of vaccine efficacy and effectiveness against SARS-CoV-2 infection, symptomatic, and severe COVID-19 was conducted in this article .
Journal ArticleDOI

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.

Andre C. Kalil, +55 more
TL;DR: In this article, the authors compared the efficacy of interferon beta-1a in combination with remdesivir in hospitalised patients with SARS-CoV-2 infection, as confirmed by a positive RT-PCR test, and the primary outcome was time to recovery, defined as the first day that a patient attained a category 1, 2, or 3 score on the eight-category ordinal scale.
Journal ArticleDOI

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Cameron R. Wolfe, +235 more
TL;DR: The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population.